Fund Houses Recommendations: ITC, Divis Lab, SAIL, Vodafone, Infosys

Ahmedabad, 16 August

BofA on Auro Pharma: Maintain Buy on Company, target price at Rs 965/sh (Positive)

Jefferies on ITC: Maintain Buy on Company, target price at Rs 530/sh (Positive)

GS on ITC: Maintain Buy on Company, target price at Rs 500/sh (Positive)

BofA on ITC: Maintain Buy on Company, target price at Rs 500/sh (Positive)

Citi on SAIL: Maintain Buy on Company, target price at Rs 110/sh (Positive)

GS on Divis Lab: Maintain Buy on Company, target price at Rs 3885/sh (Positive)

Jefferies on Divis Lab: Maintain Buy on Company, target price at Rs 4300/sh (Positive)

Citi on Crompton: Maintain Buy on Company, target price at Rs 350/sh (Neutral)

MS on IBul housing: Maintain Underweight on Company, target price at Rs 103/sh (Neutral)

HSBC on Auro Pharma: Maintain Hold on Company, target price at Rs 855/sh (Neutral)

JP Morgan on ITC: Maintain Overweight on Company, target price at Rs 475/sh (Neutral)

MS on ITC: Maintain Overweight on Company, target price at Rs 493/sh (Neutral)

CLSA on ITC: Maintain Outperform on Company, target price at Rs 480/sh (Neutral)

UBS on Vodafone: Maintain Neutral on Company, target price at Rs 7.7/sh (Neutral)

JP Morgan on Infosys: Maintain Underweight on Company, target price at Rs 1150/sh (Neutral)

HSBC on Divis Lab: Maintain Reduce on Company, target price at Rs 2890/sh (Neutral)

BofA on Divis Lab: Maintain Underperform on Company, target price at Rs 3150/sh (Neutral)

Nomura on Crompton: Downgrade to Neutral on Company, target price at Rs 338/sh (Negative)

 (Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)

(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ, ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો.)